Assuntos
Anti-Inflamatórios/efeitos adversos , Anticorpos Monoclonais Humanizados/efeitos adversos , Mucinoses/induzido quimicamente , Dermatopatias/induzido quimicamente , Feminino , Arterite de Células Gigantes/complicações , Arterite de Células Gigantes/tratamento farmacológico , Humanos , Pessoa de Meia-Idade , Mucinoses/patologia , Dermatopatias/patologia , Espondiloartropatias/complicaçõesRESUMO
Nodular lichen myxoedematosus is a localised form of lichen myxoedematosus, a chronic idiopathic cutaneous mucinosis of known aetiology. Ustekinumab is a human interleukin-12/23 monoclonal antibody that could directly or indirectly increase mucin production. Herein, we report for the first time a case of nodular lichen myxoedematosus associated with ustekinumab.
Assuntos
Toxidermias/etiologia , Fármacos Gastrointestinais/efeitos adversos , Erupções Liquenoides/induzido quimicamente , Mucinoses/induzido quimicamente , Ustekinumab/efeitos adversos , Adulto , Doença de Crohn/tratamento farmacológico , Toxidermias/patologia , Humanos , Erupções Liquenoides/patologia , Masculino , Mucinoses/patologiaAssuntos
Anticorpos Monoclonais/efeitos adversos , Fármacos Dermatológicos/efeitos adversos , Mucinoses/induzido quimicamente , Adulto , Anticorpos Monoclonais/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Humanos , Infliximab , Masculino , Psoríase/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidoresRESUMO
46-year-old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta-1b subcutaneously for multiple sclerosis. Skin biopsy revealed multiple superficial thrombosed vessels with focal epidermal necrosis as well as prominent interstitial mucinosis. Treatment with low-molecular-weight heparin followed by a heparinoid resulted in slow healing of the ulcers but also allowed the subcutaneous interferon injections to be continued.
Assuntos
Parede Abdominal , Adjuvantes Imunológicos/efeitos adversos , Interferon beta/efeitos adversos , Mucinoses/induzido quimicamente , Úlcera/induzido quimicamente , Adjuvantes Imunológicos/administração & dosagem , Sulfatos de Condroitina/uso terapêutico , Dermatan Sulfato/uso terapêutico , Enoxaparina/uso terapêutico , Feminino , Fibrinolíticos/administração & dosagem , Heparitina Sulfato/uso terapêutico , Humanos , Injeções Subcutâneas , Interferon beta-1b , Interferon beta/administração & dosagem , Pessoa de Meia-Idade , Mucinoses/patologia , Esclerose Múltipla/tratamento farmacológico , Trombose/induzido quimicamente , Trombose/tratamento farmacológico , Resultado do Tratamento , Úlcera/patologiaRESUMO
A 59-year-old Caucasian suffering from chronic hepatitis C started daily subcutaneous self-injections of interferon alfacon-1 (consensus interferon) according to the protocol of a randomised multicentre study. At week 10, he developed painful erythematous lesions at two injection sites. Consensus interferon dosage was reduced, and eventually, the lesions healed with small areas of scarring due to central necrosis. At week 51, again large areas of erythematous thickened skin arose at two other injection sites followed by substantial ulceration and central necrosis. Skin biopsy revealed excessive dermal mucin deposition so that cutaneous mucinosis was diagnosed. After 3-6 months, the lesions healed with central scarring. Due to a persistently negative HCV-PCR from serum (from week 12 onwards), consensus interferon treatment was not stopped but continued until week 60 according to the study protocol. - Cutaneous mucinosis has not been previously reported to complicate treatment with consensus interferon in patients with chronic hepatitis C and should therefore be added to the list of dermatological side-effects associated with interferon alfacon-1 therapy.